PMS29 Cost Of Best Supportive Care In The Treatment Of Moderate-To-Severe Psoriatic Arthritis In The United States  by Tencer, T. et al.
A222 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  
  
 
insurance, bringing the average annual burden to €1600 for these patients. 
CONCLUSIONS: The annual medical cost of RA is significantly lower in Turkey 
relative to European estimates. With higher expenditures, there is a potential for 
a decrease in disease activity.  
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OBJECTIVES: To explore the direct health care resources associated with 
ankylosing spondylitis (AS) in Turkey, and establish how treatment intensity, 
proxied by AS treatment expenditures, affects disease activity. METHODS: 
Medical records of 650 prevalent AS patients attending seven centers at tertiary 
health care institutions nationwide were examined to assess the annual direct 
health care costs. Eligible patients were age ≥18 and diagnosed with AS for at 
least 12 months. To identify direct costs, overall costs were categorized as 
inpatient, outpatient, pharmacy and copay. Generalized linear models were used 
to determine factors affecting annual health care costs. Costs were adjusted by 
exchange rate of €1=2.30 Turkish Lira. RESULTS: The average patient age was 
40.1±11.33 standard deviation (SD) years and 35% of AS patients were female. 
Average disease duration was 7.9 years and more than 25% of patients suffered 
from at least one comorbidity. 7.54% of AS patients received inpatient care, 
92.77% received outpatient care and 95.23% weAre prescribed at least one 
medication. 66.77% of patients were prescribed disease-modifying anti-
rheumatic drugs (DMARDs). The mean (median) annual cost per patient was 
€6,059 (€6,825). The most significant portion of overall expenditures was due to 
drug cost (€5,728), while outpatient costs totaled €254 and inpatient costs €68. 
Copayments were relatively low at €12.3. Age and gender had no effect on 
annual health care costs. 54.92% of AS patients experienced work loss due to 
their condition. On average, annual cost due to work loss was calculated at €412. 
Two percent of patients also had other AS-related consultations, which were not 
covered by insurance. The average annual burden for these patients was €2482. 
CONCLUSIONS: Inpatient and outpatient costs for AS patients are lower in 
Turkey relative to other European countries. Treatment intensity inversely 
affects GDA, indicating that GDA can be improved by increasing treatment 
intensity.  
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OBJECTIVES: The introduction of biologic therapies has dramatically changed  
the management of psoriatic arthritis (PsA). The study aimed to estimate long-
term costs of biologics in the treatment of psoriatic arthritic patients in the 
United States. METHODS: We developed a 10-year Markov model describing the 
treatment pathway of patients with psoriatic arthritis who had failed prior  
oral DMARD therapy, using monthly cycles. Clinical efficacy data were obtained 
from published pivotal study results and literature. Costs, resource utilisation 
and treatment pathways were obtained from literature and expert opinion. 
Patients transitioned through two lines of biologics (etanercept, infliximab, 
golimumab or adalimumab as first or second line) followed by best supportive 
care. Response to therapy was defined as the probability of PsARC response at 
the end of the trial period. Patients transitioned to the next line of therapy in 
case of non-response or discontinuation due to other causes (a short-term 
annual drop-out rate of 32% and a long-term rate of 16.5% were assumed). All-
cause death was included and adjusted to reflect the increased mortality 
associated with PsA. Treatment and administration, monitoring, and 
hospitalisation costs were included. An annual discount rate of 3% was used. 
Probabilistic sensitivity analysis was conducted on key model parameters. For 
each first-line biologic option, average results across second-line biologic 
therapies were reported. RESULTS: From a third-party payer’s perspective, the 
estimated 10-year cumulative direct costs per patient were $214,642 (95% Crl: 
$214,171; $221,074) with etanercept as first-line biologic therapy, $203,140 (95% 
CrI: $202,632; $208,398) with infliximab, $218,703 (95% Crl: $217,992; $224,255) 
with golimumab and $208,840 (95% CrI: $208,192; $215,014) with adalimumab. 
Across scenarios, drug costs represented between 89.4% and 91.1% of total costs, 
monitoring costs between 4.5% and 6.3%, and hospitalisation costs between 4.3% 
and 4.9%. CONCLUSIONS: Biologic therapies represent a significant cost burden 
to payers.  
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OBJECTIVES: To determine health care costs of patients with rheumatoid 
arthritis (RA) from a single health plan who switch first- and second-line biologic 
disease-modifying antirheumatic drug (bDMARD) therapy. METHODS: This 
observational, retrospective analysis utilized administrative claims from a large, 
commercial health plan database containing insured beneficiaries between 
January 1, 2006 and December 31, 2010. The first-line population consisted of 
patients with RA, newly initiated on abatacept, etanercept, infliximab or 
adalimumab, with 12 months of continuous follow-up. A new second-line 
patient cohort was defined as those initiating a bDMARD with evidence of a 
different bDMARD up to 2 years prior to index date. Switching was defined as a 
different bDMARD claim within a 200% gap in days supply from the previous 
bDMARD claim. The days supply for bDMARDs was imputed based on the 
product label. Among switchers, the post-index period was divided into post-
initiation pre-switch and post-switch periods. All post-index costs were monthly 
and calculated only for the time the patient was on a bDMARD. Bivariate and 
multivariate statistical analyses were conducted to determine costs of bDMARD 
switchers versus non-switchers. RESULTS: Patients who switched first-line 
bDMARD therapy had higher baseline monthly health care costs than non-
switchers ($2417 vs. $2081; p<0.001). Post-index, first-line switchers had 
significantly higher costs after switch than non-switchers ($6081 vs. $4415), as 
did second-line switchers ($8376 v.s $5625). After controlling for potential 
confounders, post-switching costs were increased by 35% (least squares [LS] 
mean $5693 vs. $4224; p<0.001) for first-line switchers and by 46% (LS mean 
$7799 vs. $5348; p<0.001) for second-line switchers, versus non-switchers. 
CONCLUSIONS: Compared with non-switchers, health care costs are 
significantly higher for both first- and second-line switchers following switch. 
These findings reinforce the importance of understanding the implications 
associated with switching bDMARD therapy.  
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OBJECTIVES: To determine the average cost of treatment incurred, to perform 
pharmacoeconomic analysis of drug therapy and to study changes in patient 
economic burden with disease activity for RA patients. METHODS: The study 
design was observational. Patient’s bill and insurance status was collected from 
the finance department for 250 RA patients. Inclusion and exclusion criteria were 
followed as per the ACR Guidelines (1987 and 2010). Patient drug therapy and 
disease activity were recorded from individual CRF& hospital records. RESULTS: 
Of 250RA patients female to male ratio was found to be 3:1. 67% of patients 
admitted were ages b/w 40–60years. The average days of hospitalization was 
found to be 7 days with average bed charges of INR 649 per patient. The total cost 
of therapy incurred per patient was INR 8961. The highest contribution was 
made by medications (INR 1920/patient), biochemical investigation charges 
(INR1561), doctor fees (INR1006), X-ray charges (INR385), physiotherapy 
procedures (INR320).These charges were found to vary within the patient 
population group based on the stage of the disease &presence/absence of co–
morbid conditions. CONCLUSIONS: Medication costs along with investigation 
charges are the highest contributors to the total expenses incurred by RA 
patients &has direct impact on HRQOL. These costs seem to vary from patient to 
patient based on Disease Activity Score and also presence of co–morbid 
conditions. Hence it becomes vital to diagnose and control the disease at an 
early stage to control the economic burden on the patient.  
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OBJECTIVES: To describe the best supportive care costs of psoriatic arthritis 
patients following discontinuation of DMARD therapy. METHODS: Adult patients 
with ≥2 PsA diagnoses (from office visits) with continuous insurance coverage ≥ 
6-month before (baseline period) and ≥12-month post-index date were selected 
from the MarketScan Commercial and Medicare Claims database (2005-2009). 
The index date was defined as the last day of DMARD coverage. Discontinuation 
was defined as no DMARD treatment for ≥12 consecutive months from the last 
day of DMARD prescription coverage. Patients were classified as having 
discontinued from a biologic if there was evidence of biologic DMARD use during 
the baseline period; otherwise they were defined as having discontinued from 
non-biologic DMARD. Twelve-month average costs following discontinuation 
were reported. RESULTS: A total of 1656 PsA patients met the selection criteria; 
63.2% were discontinued on non-biologic DMARD therapy and 36.8% on biologic 
therapy. Of non-biologic DMARD users, 59.7% were on methotrexate and 40.3% 
on other DMARDS. Over the 12-month period following discontinuation, total 
costs were $14,359 (SD: 23,375) and $10,144 (SD: 17,312) for biologic and non-
biologic users, respectively (p < 0.001). Outpatient and hospital/ER costs were 
significantly higher for the biologic discontinuers compared to the non-biologic 
discontinuers ($7,606 vs. $5,429, p=0.002, and $3,439 vs. $2,066, p<0.013, 
respectively) and accounted for 77% and 74% of total costs, respectively. 
Similarly, biologic users had higher drug costs ($3,314 vs. $2,649, p <0.002, 
respectively). CONCLUSIONS: This study suggests that outpatient and 
hospital/ER costs account for a substantial proportion of health care costs in PsA 
patients who discontinued from DMARD therapy. Patients who had discontinued 
from biologic DMARD therapy incurred higher outpatient, hospital and drug 
costs compared to patients who had discontinued from non-biologic DMARD 
therapy.  
